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A B S T R A C T
Background: The exact effects of alcohol drinking on cardiac function are not clear.
Aims: This study aimed to determine the relationship between consumed amount of alcohol, myocar-
dial injury, and prognosis.
Methods: Myocardial function and cardiac outcomes were examined in subjects with chronic alcoholism 
by classical and strain echocardiographic parameters, including global (GLS) and layer-specific longitudi-
nal strain of the endocardial (GLSendo) and epicardial (GLSepi) layer. One group of 65 alcohol-overusers 
(ALC), median (IQR, interquartile range) age 44 (38–51) years, was compared with 30 controls (CG).
Results: Median (IQR) alcohol dose (in alcohol units, 1 AU = 1 g of ethanol) per week was 30 (12–51) AU 
in ALC and 0 in CG; P <0.001, and the mean (SD, standard deviation) drinking period was 16 (9) years. ALC 
patients demonstrated higher left ventricular (LV) mass and impaired diastolic function. The ALC group 
demonstrated lower median (IQR) LV ejection fraction (EF): 52% (37%–57%) vs 60% (55%–63%) (P <0.001); 
GLS: 17% (9%–20%) vs 19% (18%–21%) (P = 0.01); absolute layer-specific strain values. GLSendo <19% 
and GLSepi <15% predicted worsened mid-term prognosis, as did elevated N-terminal brain natriuretic 
peptide (NT-proBNP) and lower EF and GLS.
Conclusions: Long-term alcohol overuse, even with a rather low reported median (IQR) dose of 4 (2–7) 
AU per day resulted in LV hypertrophy, diastolic and systolic dysfunction. Diminished GLS <18%, endo-
cardial <19% and epicardial <15% layer strain predicted combined endpoints but did not significantly 
improve the prognostic power of tested models, based on NT-proBNP and EF in follow-up.
Key words: alcohol induced cardiomyopathy, left ventricular hypertrophy, diastolic function, left atrial 
volume index, global longitudinal strain, layer-specific strain.
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It was estimated by the World Health Organzation in 
2018 that 2.4 billion people, i.e., 43% of the global popula-
tion over 15 years old, consumed alcohol [1]. In particular, 
western countries have a higher incidence of dilated car-
diomyopathy with an alcoholic etiology, ranging from 4% 
to 47% [2, 3]. Even so, the pathophysiology of alcohol-in-
duced myocardial damage remains unclear, and there 
is a need for deeper study of the relationship between 
the consumed ethanol dose and severity of myocardial 
injury and outcomes. Novel imaging modalities provide 
an opportunity for more sensitive assessment of heart 
damage [4]. Deformation parameters with the leading 
global longitudinal strain allow myocardial function to 
be characterized quantitatively, and often more precisely 
than conventional variables. Furthermore, the myocardial 
wall can be divided into tiers according to the dominant 
direction of myocardial fibers (viz. endo-, epi- and mid-
wall layers), which may be followed separately during 
deformation assessment [4].
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W H A T ’ S  N E W ?
To our knowledge, this is the first study to compare the diagnostic and prognostic value of layer-specific strain with classical 
echocardiography parameters in chronic alcohol abusers. Our findings indicate that long-term alcohol overuse, mean (SD, 
standard deviation) value of 16 (9) years, with a rather low reported median (IQR, interquartile range) alcohol dose of 4 (2–7) 
alcohol units per day caused left ventricle hypertrophy, diastolic and systolic dysfunction with an increase in left atrium volume 
and the impairment of global longitudinal strain. Univariate analysis found that elevated N-terminal brain natriuretic peptide, 
decreased ejection fraction and impaired global and layer longitudinal strain were related to worsened prognosis. Calculated 
cut-off values for global longitudinal left ventricular strain <18%, global longitudinal epicardial strain <15% and global longitu-
dinal endocardial strain <19% may have diagnostic and prognostic potential; however, they did not add any significant benefit 
to classical parameters in the small scale of the present study.
METHODS
Patient population
Clinical and laboratory data was collected from two groups, 
viz. alcohol over-users (ALC) and controls (CG) over the pe-
riod 2015–2020. The alcohol dose was expressed in alcohol 
units (AU), with one AU representing ten grams of pure eth-
anol, irrespective of beverage type. The declared amount of 
alcohol consumed during a patient’s life, i.e., total dose (TD), 
was expressed in AU, expressed as liters. Daily or weekly 
alcohol dose was calculated as TD divided by a period of 
time, i.e., AUD being alcohol units per day and AUW being 
alcohol units per week. The approximate accuracy of the 
declared alcohol dose was indirectly verified with the 
Michigan Alcohol Screening Test (MAST), which indicates 
whether the patient is addicted to alcohol and assesses 
addiction severity. Patients with a MAST score <4 (very low 
risk of alcohol addiction) were not included in the study.
The ALC group was formed by consecutive patients with 
history of alcohol overuse hospitalized in four departments 
of Biegański Memorial Hospital: the Department of Internal 
Diseases and Geriatrics, the Department of Internal Diseas-
es and Clinical Pharmacology, the Cardiology Department, 
as well as the Department of Infectious Diseases and Hepa-
tology. The study was approved by the Medical University 
of Lodz Ethics Committee and all patients provided written 
informed consent to participate in the study.
The inclusion criteria comprised the following: age 
>18 years, reported alcohol overuse ≥10 AUW in any period 
of patient’s life, recruitment to the ALC group, sinus rhythm 
at the time of examination. In addition, informed consent 
had to be given for the study and follow-up.
The exclusion criteria included any of the following: 
diagnosed coronary artery disease (history of myocardial 
infarction, revascularization), strong clinical suspicion of 
coronary artery disease with typical chest pain, positive for 
ischemia results of stress tests or scintigraphy, significant 
lesions in coronary angiography, persistent or permanent 
atrial fibrillation, diagnosed cardiomyopathies, primary 
significant valve diseases or pregnancy.
The CG was formed by patients without symptoms 
or coronary artery disease, diabetes or uncontrolled hy-
pertension or any cardiomyopathies or valve diseases. All 
patients denied regular alcohol consumption: sporadic 
consumption ≤2 AU per week was allowed and reported 
by three subjects.
Echocardiographic data collection
Echocardiographic examinations were performed with an 
E9 or E95 Vivid Ultrasound System (GE Healthcare, Horten, 
Norway) and transferred to a workstation for off-line analysis 
(EchoPAC, version 201, GE Healthcare). Global longitudinal 
strain (GLS), endocardial (GLSendo) and epicardial strain 
(GLSepi) were displayed as absolute values of myocardi-
al shortening. Echocardiographic measurements were 
performed according to recent guidelines. The following 
norms were adopted: GLS ≥19.7%, GLSendo ≥24.1%, 
GLSepi ≥19.2% [5–9]. Strain parameters were obtained based 
on high-quality 2D images with 70–90 frames per second.
Statistical analysis
Data analysis was performed with MedCalc version 
12.7.0.0 (MedCalc Software Ltd, Ostend, Belgium) and Ex-
cel version 14.0.7237 (Redmond, WA, USA). Variables were 
classified as normally or non-normally distributed with the 
D’Agostino-Pearson test. Quantitative variables with a nor-
mal distribution were presented as means and standard 
deviations (SD), and those with a non-normal distribution as 
medians and interquartile ranges (IQR). The results for cate-
gorical variables are presented as percentages. Qualitative 
data was compared using the chi-square test and the Fisher’s 
exact test. Quantitative variables were compared using the 
Student’s t-test for normal distributions, or the Mann-Whit-
ney test for non-normal distributions. The correlation coef-
ficient was calculated as the Pearson’s or Spearman’s coeffi-
cient for normal and non-normal distribution respectively. 
The combined endpoint was defined as cardiac-related 
hospitalization, i.e., heart failure (HF) exacerbation, myocar-
dial infarction or ischemia or arrhythmias, or cardiac death. 
Survival data was analyzed with the Kaplan-Meier method 
and displayed as the Kaplan-Meier curve. Exact Binomial 
Confidence Intervals for the Area Under the Curves (AUC) 
in ROC analysis were calculated and, in the next step, AUC 
comparison was performed by DeLong method. 
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RESULTS
Clinical and laboratory characteristics
The ALC group consisted of 65 patients, 50 (77%) of whom 
were men. The median (IQR) age was 44 (38–51) years. CG 
consisted of 30 patients, 22 (66%) of whom were men. Both 
groups were similar, according to age, sex, and systolic 
(SBP) and diastolic (DBP) blood pressure, see Table 1. The 
median (IQR) weekly alcohol dose (AUW) was 30 (12–51) 
AU for ALC and 0 (0–0) AU for CG (P <0.001). The median 
(IQR) total alcohol dose (TD) was 201 (6–34) liters of pure 
ethanol in ALC vs 0 (0–0) in CG. 
The mean (SD) time of alcohol consumption declared by 
patients was 16 (9) years. The median (IQR) time between 
the last alcohol ingestion and echocardiography exam-
ination, i.e., free time (FT), was 10 (7–21) days. The most 
popular type of drink was vodka, as well as other forms of 
distilled alcohol, with 26% of patients reported drinking it 
as a solo beverage and 87% with another type of alcoholic 
drink, such as beer or wine. The mean (SD) MAST score was 
25 (10), which indicated a high level of alcohol addiction 
in the studied group. 
The prevalence of arterial hypertension was similar be-
tween the groups, although more intensive hypertension 
therapy was observed in ALC. In addition, smoking was 
more prevalent in the ALC group (51%) than the CG group 
(6%) (P = 0.002; Table 1). 
In the electrocardiogram, an atrioventricular first-de-
gree block was present in three patients, left bundle branch 
block in two, right bundle branch block and left anterior 
hemiblock in one patient each. There were no additional 
ST segment abnormalities. 
The ALC group demonstrated a higher median N-termi-
nal brain natriuretic peptide (NT-proBNP) level, i.e. 414 (97–
–1774) pg/ml, than the CG group, i.e. 44 (39–311) pg/ml 
(P <0.001; Supplementary material, Figure S1). ALC also 
demonstrated higher median (IQR) corpuscular volume 
(MCV), i.e., 101 fL (36–123), than the CG group, 90 fL (83–92); 
P <0.001 and a higher serum aspartate transaminase level 
(AST): 64 lU/L (40–147) vs 18 lU/L (17–24) (P = 0.01; Table 2).
Table 1. Clinical characteristics
Alcohol overuse group (n = 65) Control group (n = 30) P-value
Age, years, median (IQR) 44 (38–51) 40 (32–55) 0.39
Sex, men, n (%) 50 (77) men 20 (66) men 0.52
BMI, kg/m2, median (IQR) 25 (22–27) 26 (22–27) 0.35
BSA, m2, mean (SD) 1.9 (0.19) 1.9 (0.18) 0.86
SBP, mm Hg, mean (SD) 121 (19) 123 (14) 0.43
DBP, mm Hg, mean (SD) 76 (12) 74 (9) 0.33
HR, bpm, mean (SD) 79 (12) 66 (13) <0.001
TD, dm³, median (IQR) 201 (6–34) 0 (0–0) <0.001
AUW, median (IQR) 30 (12–51) 0 (0–0) <0.001
Comorbidities, pharmacological therapy and symptoms
Arterial hypertension, n (%) 25 (39) 5 (17) 0.06
Dyslipidemia, n (%) 26 (40) 9 (30) 0.48
Diabetes, n (%) 7 (11) 2 (6) 0.69
Chronic kidney disease, n (%) 2 (3) 1 (3) 0.52
Gastritis, n (%) 6 (9) 0 (0) 0.17
Alcoholic hepatis steatosis/inflammation, 
n (%)
19 (29) 0 (0) 0.002
Hepatic cirrhosis, n (%) 18 (28) 0 (0) 0.003
Esophageal varices, n (%) 5 (8) 0 (0) 0.17
Cholelithiasis, n (%) 2 (3) 0 (0) 1.0
COPD, n (%) 3(5) 0 (0) 0.55
Smoking, n (%) 33 (51) 2 (6) 0.002
β-blockers, n (%) 50 (85) 6 (20) <0.001
Ivabradine, n (%) 5 (8) 0 (0) 0.17
ACEI/ARB, n (%) 25 (42) 6 (20) 0.06
Spironolactone, n (%) 36 (61) 0 (0) <0.001
Diuretics, n (%) 33 (56) 0 (0) <0.001
Calcium antagonists, n (%) 3 (5) 2 (7) 0.65
Statins, n (%) 11 (19) 9 (30) 0.18
NYHA 0, n (%), no symptoms 7 (11) 30 (100) <0.001
NYHA I, n (%) 27 (42) 0 (0)
NYHA II, n (%) 28 (44) 0 (0)
NYHA III, n (%) 2 (3) 0 (0)
NYHA IV, n (%) 0 (0) 0 (0)
Abbreviations: ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; AUW, alcohol units per week; BMI, body mass index; BSA, body surface 
arena; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; H`R, heart rate; NYHA, New York Heart Association class; SBP, systolic blood pressure; SD, 
standard deviation; TD, total dose of alcohol during whole life
784
K A R D I O L O G I A  P O L S K A ,  2 0 2 1 ;  7 9  ( 7 – 8 )
w w w . j o u r n a l s . v i a m e d i c a . p l / k a r d i o l o g i a _ p o l s k a
Echocardiography characteristics
The ALC and CG groups demonstrated similar left ven-
tricular diastolic and systolic diameters, but a significant 
difference was observed for intraventricular septum (IVS) 
and posterior wall thickness (PW) (Table 3). The median 
(IQR) left ventricular mass index (LVMI) was 119 (91—155) 
g/m² in ALC and 93 (75–110) g/m² in CG (P = 0.002; Figure 1). 
Systolic function, expressed as median (IQR) left ventricu-
lar (LV) ejection fraction (EF), was impaired in ALC: 52% 
(37%–57%) vs 60% (55%–63%) in CG (P <0.001), as well as 
a few diastolic function parameters. 
The prevalence of abnormal EF (defined as EF <50%) 
was 38% in the ALC group vs 0% in CG (P <0.001). The 
ALC group demonstrated significant enlargements for all 
dimensions of the left atrium (LA): LA diameter, LA vol-
ume and volume index (LAVI), as indicated in Table 3 and 
Figure 1. The median (IQR) E/A ratio was higher in CG, i.e. 
1.3 (1.1–1.4) than ALC, i.e. 1.1 (0.8–1.2) (P = 0.01); in addition, 
the mean (SD) E wave velocity was higher in CG, i.e. 83 (18) 
than in ALC, i.e. 70 (19) (P = 0.03); however, the median 
(IQR) E/e’ ratio was higher in ALC: 7.4 (5–10) than in CG, 
6.1 (5.0–6.7) (P = 0.006). 
However, no significant differences were observed re-
garding the mean values for the classical right ventricular 
parameters: tricuspid annular plane systolic excursion or 
right ventricle S’ wave velocity (Table 3).
The strain data was described in absolute values. The 
median (IQR) global longitudinal LV strain (GLS) values 
were 17% (9%–20%) in ALC vs 19% (18%–21%) in CG 
(P = 0.01). Both median (IQR) layer strains were lower in 
ALC: median (IQR) GLSendo was 19% (12%–23%) vs 24% 
(21%–27%) (P = 0.007) and GLSepi was 14% (9%–18%) vs 
19% (16%–20%) (P = 0.007), as indicated in Table 3 and 
Figure 2. 
EF <50% was observed in 38% of ALC patients and ele-
vated LAVI (>34 ml/m2) in 51%. In contrast, none of the CG 
patients demonstrated any such impairments (P <0.001). 
Deformation impairment, expressed as GLS <19.7%, was 
present in 45 patients (69%) of the ALC group, and in 
10 controls (33%) (P = 0.002; Table 3).
Table 2. Laboratory characteristics
Alcohol group (n = 65) Control group (n = 30) P-value
NT-proBNP, pg/ml, median (IQR) 414 (97–1774) 44 (39–311) <0.001
MCV, fL, median (IQR) 101 (36–123) 90 (83–92) <0.001
Creatinine, mg/dl, median (IQR) 0.8 (0.6–0.9) 0.7 (0.7–1.0) 0.78
AST, IU/l, median (IQR) 64 (40–147) 18 (17–24) 0.01
ALT, IU/l, median (IQR) 42 (26–86) 22 (17–44) 0.23
De Ritis ratio (AST/ALT), median (IQR) 1.4 (0.85–2.55) 1.2 (1.0–1.8) 0.75
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; MCV, mean corpuscular volume; NT-proBNP, N-terminal brain natriuretic peptide
Table 3. Echocardiography characteristics, alcohol versus control group
Alcohol group (n = 65) Control group (n = 30) P-value
LVd, mm, mean (SD) 48 (12) 48 (4)  0.14
LVs, mm, median (IQR) 28 (23–40) 32 (31–35)  0.06
IVSd, mm, mean (SD) 13 (3) 9 (1) <0.001
PWd, mm, median (IQR) 12 (11–14) 10 (9–11) <0.001
LVMI, g/m2, median (IQR) 119 (91–155) 93 (75–110) 0.002
RWT, median (IQR) 0.5 (0.4–0.6) 0.4 (0.4–0.4) 0.001
LA, mm, mean (SD) 43 (8) 36 (5) 0.005
LAV, ml, median (IQR) 67 (49–86) 40 (36–49) <0.001
LAVI, l/m2, median (IQR) 34 (25–45) 21 (18–23) <0.001
TAPSE, mm, median (IQR) 22 (20–26) 22 (21–26) 0.47
RVS’, cm/s, mean (SD) 12 (3) 13 (2) 0.11
E/A, median (IQR) 1.1 (0.8–1.2) 1.3 (1.1–1.4) 0.01
E, m/s, mean (SD) 70 (19) 83 (18) 0.03
E/e’, median (IQR) 7.4 (5–10) 6.1 (5.0–6.7) 0.006
EF, %, median (IQR) 52 (37–57) 60 (55–63) <0.001
GLS, %, median (IQR) 17 (9–20) 19 (18–21) 0.01
GLSendo, %, median (IQR) 19 (12–23) 24 (21–27) 0.007
GLSepi, %, median (IQR) 14 (9–18) 19 (16–20) 0.007
EF <50%, n (%) 25 (38) 0 (0) <0.001
LVMI, female/male >115/95 g/m2, n (%) 35 (55) 6 (22) 0.008
LAVI >34 ml/m2, n (%) 33 (51) 0 (0) <0.001
GLS <19.7%, n (%) 45 (69) 10 (33) 0.002
Abbreviations: E/A, wave E velocity to wave A velocity ratio; EF, left ventricular ejection fraction; GLS, global longitudinal left ventricular strain; GLSendo, global longitudinal 
endocardial strain; GLSepi, global longitudinal epicardial strain; IVSd, interventricular septum diastolic thickness; LA, left atrial diameter; LAV, left atrial volume; LAVI, left atrial 
volume index; LVd, left ventricular diastolic diameter; LVMI, left ventricular mass index; LVs, left ventricular systolic diameter; PWd, posterior wall diastolic thickness; RVS’, wave 
S’ velocity; RWT, relative wall thickness; SD, standard deviation; TAPSE, tricuspid annular plane systolic excursion
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Alcohol group Control group
Figure 1. Increased left ventricular mass index and atrial volume index in the alcohol group as compared to the control group. A. Left ventric-
ular mass index. B. Left atrial volume index.
Abbreviations: LAVI, left atrial volume index; LVMI, left ventricular mass index
A B
Figure 2. Comparison between the normal (upper panel) and severely impaired myocardial wall deformation expressed by layer-specific 
strain, in a control subject and a patient from the alcohol group. Upper panels — preserved deformation in a 65-year-old male, arterial 
hypertension, dyslipidemia, alcohol units per week = 0. Lower panels — a 63-year-old male with severe impaired deformation, total alcohol 
dose = 22600 alcohol units, reported alcohol units per week = 11, arterial hypertension, dyslipidemia and smoking, but coronary angiogra-
phy revealed no flow limitations. A. Four-chamber apical view strain regions in a patient with preserved deformation. B. Left ventricular polar 
map — “bull’s eye” of global longitudinal endocardial strain in a patient with preserved deformation. C. Left ventricular polar map — “bull’s 
eye” of global longitudinal epicardial strain in a patient with preserved deformation. D. Four-chamber apical view strain regions in a patient 
with impaired deformation. E. Left ventricular polar map — “bull’s eye” global longitudinal endocardial strain in a patient with impaired 
deformation. F. Left ventricular polar map — “bull’s eye” global longitudinal epicardial strain in a patient with impaired deformation
A B C
D E F
In the ALC group, the prevalence of abnormal GLS and both 
layer strains were significantly higher in patients with EF <50% 
than in those with preserved EF. Among those with reduced 
EF, impaired GLS was observed in 22 patients (88%) whereas 
impaired GLSendo and GLSepi were present in 24 (96%). 
Among those with preserved EF, impaired GLS was observed 
in 23 patients (57%) (P = 0.02), and lowered GLSendo/GLSepi 
in 26 patients (65%) (P <0.001), for both layer strains.
The parameter which in the best manner differentiated 
ALC and CG was LAVI, which outperformed LVMI and GLS 
as well as GLSendo whereas, EF <51% (AUC, 0.770; 95% 
confidence interval [95% CI], 0.672–0.850) and GLSepi 
<15.3% (AUD, 0.742; 95% CI: 0.642–0.826) were not signif-
icantly inferior to LAVI. LAVI >24.5 ml/m2, for the detection 
of alcohol overusing patients, achieved the highest value 
among tested parameters (with the area under the curve 
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[AUC] ROC, 0.848 and with 95% CI, 0.758–0.915. This pa-
rameter outperformed 3 other tested parameters: LVMI 
>118 mg/m2 (AUC, 0.704; 95% CI, 0.599–0.795), P = 0.02; GLS 
<17.1% (AUC, 0.695; 95% CI, 0.592–0.785); P = 0.01; GLSen-
do <19.9% (AUC, 0.694; 95% CI, 0.591–0.785); P = 0.04.
Correlation analysis revealed a very strong relationship 
between GLSendo, GLSepi and GLS, and GLSendo, GLSepi 
and EF (P <0.001 for all) (Supplementary material, Figure S2). 
A significant correlation was also observed for GLSendo, 
GLSepi and NT-proBNP, with a rho value of 0.62 (P <0.001) 
for both variables. 
The significant positive correlation was observed be-
tween FT and GLS (rho = 0.26, P = 0.03), as well as a slight-
ly stronger one between FT and GLSendo and GLSepi 
(rho = 0.31, P = 0.01; rho = 0.30; P = 0.01, respectively).
Prognostic value
Follow-up by direct contact with the patient was achieved 
in 47 participants (72%) and life status (dead/alive) was 
confirmed in all. During follow-up, which lasted for mean 
28 (16) months, 11 patients reached the combined end-
point. Ten hospitalizations were recorded and assessed as 
HF exacerbation, according to the patients’ reports. In eight 
cases, hospitalization was related to peripheral edema 
and dyspnea and in two cases to symptomatic arrhyth-
mias. Death was reported by the patient’s relatives as of 
cardiac origin. 
A comparison between outcome-free patients and 
the group with combined endpoint found the group with 
worse prognosis to have significantly higher NT-proBNP, 
as well as lower EF and lower absolute values for all strain 
parameters (Table 4).
The ROC curve analysis found NT-proBNP with a cut-off 
value >2058 pg/ml to have 0.733 AUC (95% CI, 0.582–0.852) 
for predicting the combined endpoint. The respective 
cut-off and ROC AUC values for the tested variables for 
detecting the combined endpoint were as follows: EF 
≤26% (AUC, 0.739; 95% CI, 0.611–0.843), GLS <18 (AUC, 
0.751; 95% CI, 0.624–0.853), GLSepi <15% (AUC, 0.750; 95% 
CI, 0.623–0.852), and GLSendo <19% (AUC, 0.747; 95% CI, 
0.620–0.850).
Adding EF to NT-proBNP increased the value of AUC 
to 0.769 (95% CI: 0.621–0.880) but this difference was not 
statistically significant (P = 0.40). Similarly, adding strain 
values slightly increased AUC ROC to 0.796 (95% CI, 0.651–
0.900); however, this value was not statistically significant 
(P = 0.24 vs NT-proBNP alone and P = 0.45 vs NT-proBNP + EF) 
(Supplementary material, Figure S3). Kaplan-Meier survival 
curves were constructed for patients with GLSepi <15% 
and GLSendo <19% (Supplementary material, Figure S4). 
DISCUSSION
Alcohol influence on cardiac function
Park et al. [10] report that LV diastolic impairment was as-
sociated with a higher alcohol consumption: diastolic dys-
function was observed in 1758 individuals (32%) in a “heavy 
drinking group” consuming 30–60 g of pure alcohol per 
day (21–42 AUW), compared to 853 (16%) in an “occasional 
drinking group” consuming <10 g of pure alcohol per day 
(<7 AUW); P <0.001. The median alcohol dose consumed by 
the heavy drinkers was similar to the median (IQR) amount 
observed in our present study, i.e., 30 AUW (12–51). In ad-
dition, diastolic dysfunction was detected in 26 subjects 
(40%) in the ALC in our present study. Moreover, Park et al. 
[10] report higher mean LVMI 78 (14) g/m2 in the “heavy 
drinking group” than the “occasional drinking group” 70 (14) 
g/m2, P <0.001. In the present study, higher median (IQR) 
LVMI was found in the ALC group, i.e., 119 (91–155), than 
controls, i.e. 93 (75–110) g/m2; P = 0.002; in addition, the 
ALC group also demonstrated thicker IVS and PW. 
Daily alcohol consumption greater than 80 g of pure 
alcohol (equal >56 AUW) for ≥5 years has been associated 
with the development of alcohol cardiomyopathy [2, 3, 11]. 
However, our findings also indicate systolic and diastolic 
dysfunction in the ALC group, who were consuming slightly 
above half the dose of alcohol, i.e., 30 AUW (12–51), but over 
a longer mean period of time, i.e. — mean (SD) 16 years (9). 
In our ALC group, 89% of patients reported symptoms corre-
sponding to New York Heart Association (NYHA) ≥I class. This 
clinical presentation may be partially related to liver disease 
or malnutrition caused by alcohol abuse [12].
Layer-specific strain in cardiac damage
LV function can be more precisely evaluated in different 
clinical settings, e.g., in ischemia detection, by including 
deformation parameters [13]. Layer-specific strain was 
found to be a marker of cardiac muscle dysfunction asso-
Table 4. The comparison of chosen parameters between groups with and without combined endpoint
Outcome free (n = 54) Combined endpoint (n = 11) P-value
NT-proBNP, pg/ml, median (IQR) 281 (93–1390) 2192 (349–4028) 0.03
EF, %, median (IQR) 53 (45–58) 37 (23–51) 0.01
LVMI, g/m2, mean (SD) 119 (43) 164 (83) 0.11
LAVI, ml/m2, median (IQR) 33 (22–64) 33 (26–43) 0.77
GLS, %, mean (SD) 16 (6) 11 (5) 0.01
GLSendo, %, mean (SD) 18 (7) 12 (6) 0.01
GLSepi, %, mean (SD) 14 (6) 9 (5) 0.01
Abbreviations: NT-proBNP, N-terminal brain natriuretic peptide, other: see Table 3
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ciated with arterial hypertension and LV hypertrophy [14, 
15]. Similarly, absolute GLS values have been found to be 
lower in toxic cardiomyopathies [16–20]. 
A study of 44 patients with hypertrophic obstructive 
cardiomyopathy found them to have a mean (SD) IVS 
thickness of 18.9 mm (7.5) and mean (SD) PW thickness of 
11.83 mm (3.42), compared to otherwise healthy controls 
with a mean (SD) IVS thickness of 8.57 mm (1.16) and mean 
(SD) PW thickness of 9.14 mm (1.42). Absolute layer-specific 
strain values were also found to be lower in the cardiomy-
opathy group: GLSendo was 15.31% (5.55%) compared to 
22.04% (2.88%); P <0.01, and GLSepi was 11.78% (4.28%) 
compared to 17.81% (2.81%) in controls; P <0.01 (14). 
In the present study, median (IQR) GLSendo absolute 
values were 19% (12%–23%) in ALC vs 24% (21%–27%) in 
CG (P = 0.007), and absolute GLSepi was 14% (9%–18%) vs 
19% (16%–20%) (P = 0.007). The presence of a better-pre-
served layer strain in our ALC group might be partly related 
to the relatively higher implementation of hypertension 
therapy. This may exert a protective effect on LV function: 
mean (SD) EF was found to increase from 34% (8%) to 39% 
(8%) (P <0.001) during six months of observation in HF pa-
tients with spironolactone added to the therapy [21]. The 
literature concerning the layer-specific strain associated 
with chronic alcohol exposure is rather sparse, and it is 
difficult to obtain accurate information about alcoholism 
severity, often due to under-rated self-reported alcohol 
consumption [22]. Nevertheless, in a study of 199 healthy 
patients, mean age 44 (5) years, 71% males, in the acute 
phase of alcohol toxicity, the mean (SD) alcohol level in 
blood sample six hours after alcohol ingestion was 1.2 (0.3) 
g/L. The mean (SD) GLSendo during alcohol exposure was 
27% (4%), significantly lower than the value taken after four 
weeks of strict alcohol abstinence, i.e. 33% (3%) (P = 0.002). 
Blood pressure, EF, heart rate, and other classical echocardi-
ographic parameters did not show any difference between 
the two examinations [23]. 
Prognostic value of layer-specific strain
Deformation parameters have demonstrated diagnostic 
and prognostic utility in a wide range of cardiac and 
non-cardiac conditions, such as ischemic heart disease 
[13], aortic stenosis [24], diabetes type 2 [25], acute hy-
perglycemia [26] or pre-eclampsia [27]. Both GLS and 
layer-specific strains (GLSendo, GLSepi) have been found 
to have predictive significance for adverse outcomes 
following acute coronary syndrome [28]. Skaarup et al. 
[28] observed that global longitudinal strain is inde-
pendently associated with the combined outcome (HF 
or cardiovascular symptom development) for lowered 
GLSendo (HR, 1.19 [1.10–1.28]; P <0.001) and GLSepi (HR, 
1.26 [1.15–1.39]; P <0.001). In our study, univariate analysis 
found elevated NT-proBNP >2058 pg/ml decreased EF 
≤26% and longitudinal strain (GLS <18%; GLSepi <15.1%; 
GLSendo <19%) were related to a worse prognosis in the 
ALC group. Logistic regression analysis found that all tested 
parameters similarly discerned the outcomes which were 
not significantly improved in models based on two or three 
variables; this was probably due to the insufficient number 
of observed endpoints.
Study limitations
The study does have some limitations. The main one is 
that it only includes a relatively small number of exam-
ined patients. This is partially related to the difficulties of 
cooperating with addicted people and lower compliance 
in direct follow-up. However, the study also places an 
emphasis on 2D longitudinal strain and LV assessment. 
Further information could be gathered by including in-
formation gathered by 3D strain variables, rotation and 
torsion analysis, as well as deformation of right ventricle. In 
addition, it is difficult to objectively quantify self-reported 
alcohol doses, which may be underrated. Furthermore, 
the duration of the follow-up was relatively short, and 
only a limited number of combined endpoints were used, 
with cardiac origin established only by phone interview. 
Finally, differences in hypertension treatment were used 
between groups; this could influence cardiac function and 
prognosis outcomes, potentially improving natural history 
of HF in the affected group.
CONCLUSIONS
Patients reporting alcohol overuse, with a mean (SD) 16 (9) 
year consumption of median (IQR) 4 (2–7) alcohol units per 
day, demonstrated the features of LV hypertrophy, left atrial 
enlargement, and LV diastolic and systolic dysfunction. 
Regarding myocardial deformation, GLS and layer 
strain showed lower absolute values in alcohol overusers 
as compared to controls; both were associated with a more 
frequent occurrence of combined endpoint: a higher 
clinical risk of death or cardiovascular hospitalization for 
GLSendo <19% and GLSepi <15%. Nevertheless, similarly 
to volumetric assessment of atrium (LAVI), quantitative 
assessment of deformation (GLS, GLSendo and GLSepi) did 
not add any significant predictive value to models based 
on EF and NT-proBNP.
Moreover, the duration of abstinence from the last 
drinking episode correlated positively with the absolute 
value of longitudinal strain; this indicates the value of 
quantitative strain data for assessing functional recovery 
based on abstinence and pharmacological treatment.
Supplementary material
Supplementary material is available at https://journals.
viamedica.pl/kardiologia_polska.
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